ESR1 and breast carcinoma: PhIP appears to bind, specifically albeit at a lower affinity than E2, to the ERα-ligand binding domain and, therefore, competes with E2 at its binding site, thereby suggesting an epigenetic mechanism for PhIP, akin to that of E2, in breast cancers [44].